Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical has called a 2026 second H shareholders class meeting to be held in Shanghai on 16 June 2026, immediately after its AGM and A shareholders class meeting. The session will ask H shareholders to consider special resolutions tied to a new general mandate for repurchasing the company’s H shares.
The proposed mandate would allow the board to buy back up to 10% of the company’s issued H shares during a defined period, subject to parallel approvals by the AGM and A shareholders and compliance with PRC laws and Hong Kong listing rules. The repurchased shares may be cancelled, held as treasury stock and used to adjust registered capital and amend the articles, potentially affecting capital structure and shareholder value.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a PRC-incorporated healthcare company listed in Hong Kong, operating across the pharmaceutical and medical industry. The group is involved in the research, manufacturing and distribution of medicines and health-related products, serving both domestic and international markets through A shares and H shares listings.
YTD Price Performance: -2.46%
Average Trading Volume: 2,558,223
Technical Sentiment Signal: Sell
Current Market Cap: HK$71B
See more insights into 2196 stock on TipRanks’ Stock Analysis page.